Literature DB >> 15774774

Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater.

Donna E Hansel1, Anirban Maitra, John W Lin, Michael Goggins, Pedram Argani, Charles J Yeo, Steven Piantadosi, Steven D Leach, Andrew V Biankin.   

Abstract

PURPOSE: Adenocarcinomas of the ampulla of Vater demonstrate a characteristic histology but vary significantly in outcome. As a consequence, prognostic factors for these cancers are poorly defined. The caudal-type homeodomain transcription factors 1 (CDX1) and 2 (CDX2) regulate axial development and intestinal differentiation. We assessed the expression of these putative intestinal epithelial-specific transcription factors and their influence on patient outcome. PATIENTS AND METHODS: Fifty-three resected carcinomas of the ampulla of Vater, 31 pancreatic ductal adenocarcinomas, and 15 extrahepatic biliary carcinomas were analyzed for CDX1 and CDX2 expression using immunohistochemistry.
RESULTS: Forty percent of carcinomas of the ampulla of Vater but less than 5% of pancreatic and biliary adenocarcinomas expressed CDX. Expression of CDX was associated with a better prognosis (P = .0009). Individually, both CDX1 (P = .02) and CDX2 (P = .02) expression were associated with a survival advantage on univariate analysis. Advanced T stage (P = .02), lymph node metastases (P = .004), and vascular space invasion (P = .0009) were associated with a poor prognosis. Multivariate analysis revealed vascular space invasion (P = .01) and CDX expression (P = .01) to be independent prognostic factors.
CONCLUSION: Expression of CDX was an independent marker of outcome in patients with resected adenocarcinoma of the ampulla of Vater. Expression of CDX may distinguish good prognosis intestinal-like tumors, which potentially arise within intestinal epithelium, from poorer prognosis pancreatobiliary tumors, which arise in adjacent pancreatic and/or biliary ductal epithelium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774774     DOI: 10.1200/JCO.2005.03.068

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma.

Authors:  Artit Jinawath; Yoshimitsu Akiyama; Yasuhito Yuasa; Chawalit Pairojkul
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-23       Impact factor: 4.553

2.  Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability.

Authors:  Fausto Sessa; Daniela Furlan; Clementina Zampatti; Ileana Carnevali; Francesca Franzi; Carlo Capella
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.064

3.  Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression.

Authors:  Ahmad Alkhasawneh; Lizette Vila Duckworth; Thomas J George; Neelam V Desai; Alex J Sommerfeld; Xiaomin Lu; Tania Zuluaga Toro
Journal:  J Gastrointest Oncol       Date:  2016-12

4.  Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.

Authors:  Michelle D Reid; Serdar Balci; Nobuyuki Ohike; Yue Xue; Grace E Kim; Takuma Tajiri; Bahar Memis; Ipek Coban; Anil Dolgun; Alyssa M Krasinskas; Olca Basturk; David A Kooby; Juan M Sarmiento; Shishir K Maithel; Bassel F El-Rayes; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

5.  Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age.

Authors:  Chi-Chuan Yeh; Yung-Ming Jeng; Cheng-Maw Ho; Rey-Heng Hu; Hsiu-Pi Chang; Yu-Wen Tien
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

6.  Bone and brain metastases from ampullary adenocarcinoma.

Authors:  Ioannis A Voutsadakis; Stergios Doumas; Konstantinos Tsapakidis; Maria Papagianni; Christos N Papandreou
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

7.  A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.

Authors:  Z-Q Jiang; G Varadhachary; X Wang; S Kopetz; J E Lee; H Wang; R Shroff; M Katz; R A Wolff; J Fleming; M J Overman
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

8.  Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater.

Authors:  Laurence Chiche; Barbara Alkofer; Jean-Jacques Parienti; Vincent Rouleau; Ephrem Salamé; Guy Samama; Philippe Segol
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

9.  Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Ellen Freed; Natsumi Irahara; Juliet Philips; Jeffrey A Meyerhardt; Jason L Hornick; Ramesh A Shivdasani; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

10.  Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

Authors:  Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.